Adial Pharmaceuticals, Analysts Coverage, Review and Target
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Adial Pharmaceuticals, Inc. (ADIL), a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder "AUD" using its lead investigational new drug product, AD04.
The company completed its IPO in July for gross proceeds of $7.32 million. On November 29th, ADIL announced the formation of a Scientific Advisory Board. The company shares saw a leap on the same day from $1.32 per share to a high of $4.26. The shares are currently trading at $3.00 per share.
ADIL analysts coverage, review and target available here READ MORE.
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/adial-pharmaceuticals/.
William Stilley, CEO of Adial Pharmaceuticals, stated, "This has been a very active period for the Company following our successful IPO in July. We are rapidly moving forward on our clinical activities related to our Phase 3 trial for AD04 and look forward to providing further updates in the very near term. Towards this end, we have expanded our senior management team with the addition of Monika Z. Rogozinska, who is helping spearhead many of our initiatives."
ADIL clinical progress, a market overview and more in this report READ MORE.
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/adial-pharmaceuticals/.
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source
